SEC Comment Letter for SELLAS Life Sciences Group, Inc. (SLS) (CIK 0001390478) (SLS) — Jan 20, 2011

SELLAS Life Sciences Group, Inc. (SLS) (CIK 0001390478)
Date: Jan. 20, 2011 · CIK: 0001390478 · Accession: 0000000000-11-003985

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 001-33958

Date

January 20, 2011

Author

Jeffrey P. Riedler

Form

UPLOAD

Company

SELLAS Life Sciences Group, Inc. (SLS) (CIK 0001390478)

Letter

January 20, 2011 Noah D. Beerman President and Chief Executive Officer RXi Pharmaceuticals Corporation 60 Prescott Street Worcester, Massachusetts 01605 Re: RXi Pharmaceuticals Corporation Form 10-K for the Fiscal Year Ended December 31, 2009 Filed March 31, 2010 Schedule 14A filed April 23, 2010 Form 10-Q for the Quarterly Period Ended March 31, 2010 Filed May 17, 2010 File No. 001-33958

Dear Mr. Beerman: We have completed our review of your fili ngs and do not have any further comments at this time. Sincerely,

Jeffrey P. Riedler Assistant Director

cc: Arthur B. Price (Ropes & Gray LLP)

Show Raw Text

January 20, 2011
 Noah D. Beerman President and Chief Executive Officer RXi Pharmaceuticals Corporation 60 Prescott Street  Worcester, Massachusetts 01605
 Re: RXi Pharmaceuticals Corporation
 Form 10-K for the Fiscal Year Ended December 31, 2009
  Filed March 31, 2010
  Schedule 14A filed April 23, 2010   Form 10-Q for the Quarterly Period Ended March 31, 2010   Filed May 17, 2010   File No. 001-33958

Dear Mr. Beerman:
  We have completed our review of your fili ngs and do not have any further comments at
this time.
Sincerely,

Jeffrey P. Riedler
Assistant Director

 cc: Arthur B. Price (Ropes & Gray LLP)

SecProbe.io